Coherus BioSciences has moved for a stay of discovery in BPCIA litigation concerning its proposed pegfilgrastim biosimilar, CHS-1701, referenced on Amgen’s blockbuster drug Neulasta.
Coherus BioSciences has moved for a stay of discovery in Biologics Price Competition and Innovation Act (BPCIA) litigation concerning its proposed pegfilgrastim biosimilar, CHS-1701, referenced on Amgen’s blockbuster drug Neulasta.
In the motion filed last week, Coherus told the court that it believes the recent regulatory delay of CHS-1701 justifies a stay in litigation; in June, the company received a complete response letter (CRL) from the FDA with respect to the biosimilar product. The agency asked Coherus to reanalyze a subset of samples with a revised immunogenicity assay. It also requested that the drug maker provide additional manufacturing-related process information, though it did not request a clinical study of CHS-1701 in oncology patients or indicate that additional process qualification lots would be needed.
On the heels of the CRL and the subsequent delay of the product, Coherus terminated approximately 30% of its workforce, or 51 employees, in an attempt to cut its operational costs by $10 million. Coherus suffered another setback when Daiichi Sankyo, the company’s partner in the development of an investigational etanercept biosimilar, CHS-0214, terminated its relationship with the biosimilar maker.
In light of its new financial outlook, Coherus told the court in its motion for a stay that “Preservation of resources is especially important to Coherus—a new start-up biosimilar company that has no products and, because of a recent FDA rejection of its drug application, will have no revenue until its anticipated mid-2018 launch of the product at issue in this case,” and claimed that “Amgen can use its vast resources to bankrupt Coherus with unnecessary litigation expenses before Coherus can launch [CHS-1701].”
The ongoing BPCIA litigation began when the California-based biosimilar developer filed a Biologics License Application for its biosimilar product in October 2016, initiating an information exchange process, or the so-called “patent dance,” with Amgen. Subsequently, Amgen filed its initial complaint in May 2017, claiming that Coherus had infringed on one of its patents—Coherus then moved to dismiss Amgen’s complaint.
Coherus claims that discovery in the case should not proceed while its motion to dismiss is pending before the court.
The court has ordered the parties to comply with a July 18 order to submit case management documents to court by August 17, 2017. After it receives the required documents, the court will hear oral arguments on Coherus’ motion to stay litigation.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.